Table 1 Univariate and multivariable Cox regression analysis for prediction of OS.

From: Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer

Parameter

At risk group

HR [95% CI]

p-value

Univariate analysis

Gender

Male (vs Female)

1.68 [0.97, 2.89]

0.064

Age

Continuous

0.99 [0.97, 1.02]

0.545

ECOG Performance status

1 (vs 0)

1.77 [0.77, 4.08]

0.179

>=2 (vs))

4.34 [1.72, 10.96]

0.002

ORR

Response (vs no response)

0.31 [0.13, 0.76]

0.010

Metastasis

Number of metastatic sites

>=2 sites (vs <2 sites)

1.31 [0.66, 2.62]

0.44

Liver metastasis

Yes (vs No)

3.05 [1.70, 5.51]

<0.001

Lung metastasis

Yes (vs No)

0.77 [0.35, 1.67]

0.505

Other sites

Yes (vs No)

1.61 [0.68, 3.83]

0.283

WCC$

Continuous

1.18 [1.11, 1.25]

<0.001

Neutrophils$

Continuous

1.19 [1.11, 1.26]

<0.001

Lymphocytes

Continuous

0.72 [0.46, 1.12]

0.143

LDH

Continuous

1.001 [1.000, 1.003]

0.003

Ca 19.9 (Log2)

Continuous

1.07 [0.99, 1.16]

0.091

CNA

Continuous

7.09 [3.19, 15.78]

<0.001

Mutational burden

Number of mutations$

Continuous

1.06 [1.01, 1.12]

0.028

Number of KRAS mutations$

Continuous

1.11 [1.07, 1.16]

<0.001

KRAS mutations present

Yes (vs No)

3.46 [1.76, 6.77]

<0.001

KRAS copy number gain

Yes (vs No)

10.94 [3.85, 31.08]

<0.001

Highest VAF

Continuous

1.07 [1.04, 1.10]

<0.001

Multivariable analysis

ECOG Performance status

1 (vs 0)

2.51 [0.98, 6.38]

0.053

>=2 (vs 0)

4.20 [1.48, 11.94]

0.007

Metastasis

Liver metastasis

Yes (vs No)

2.83 [1.28, 6.24]

0.010

Mutational burden

KRAS copy number gain

Yes (vs No)

3.47 [1.19, 10.17]

0.023

Highest VAF

Continuous

1.05 [1.01, 1.08]

0.005

  1. Abbreviations: ORR, objective response rate (clinical outcome variable); VAF: variant allele frequency; ECOG, Eastern Cooperative Oncology Group; WCC: white cell count; $, Excluded from stepwise model building due to collinearity.
Back to article page